All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES by Brownlee, WJ & Ciccarelli, O
All relapsing multiple sclerosis patients should be managed at a specialist clinic- YES 
 
Dr W J Brownlee FRACP1  
O Ciccarelli FRCP1,2 
 
 
1 Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute 
of Neurology, London, United Kingdom  
2 NIHR University College London Hospitals Biomedical Research Centre, London, United 
Kingdom  
 
 
 
Corresponding author: Dr W Brownlee, Box 112, National Hospital for Neurology and 
Neurosurgery, Telephone +44 20 3108 7409, Fax +44 20 3448 3125, Email 
w.brownlee@ucl.ac.uk 
 
 
 
 
 
 
 
 
Past generations of neurologists frequently took the approach of “diagnose and adios” to 
managing patients with multiple sclerosis (MS). It is now generally accepted that MS is a 
chronic but treatable illness that requires long-term care from a neurologist. A recent study 
examining healthcare utilization in the United States found that although routine neurological 
care for MS was more expensive than primary care alone, there was a decrease in hospital 
admissions and emergency department visits.1 The role of neurologists in managing MS is 
reflected in recent National Institute of Health and Care Excellence (NICE) guidelines in the 
United Kingdom that recommend annual neurological review for all people with MS.2  
 
Relapsing-remitting MS (RRMS) has seen major changes over the last 20 years with new 
diagnostic criteria and new therapeutic options. The management of RRMS patients is 
becoming more complex and challenging because of the need to diagnose MS early and 
accurately, the recommendation to initiate treatments early and consider treatment 
escalation, the need to identify and treat co-morbidities and consider symptomatic 
treatments. All RRMS patients should have access to a specialist MS clinic, so that they can 
benefit from an effective management plan, which will maximise their quality of life and 
improve long-term outcomes. We will now discuss in more details the aspects of the 
disease, which we suggest should be managed at a specialist clinic. 
 
A referral to a specialist MS clinic offers an opportunity to ensure the diagnosis of MS is 
correct. The rate of misdiagnosis of MS may be is as high as 5-10%.3 The misdiagnosis of 
MS has a significant impact on patient care (misdiagnosed patients are often treated with 
disease-modifying treatments4) and the costs of the health care system. The most common 
alternative diagnoses in people misdiagnosed with MS are non-specific white matter 
abnormalities, small vessel disease and migraine.3, 4 This suggests both an inappropriate 
use of imaging criteria to diagnose MS5 and an erroneous interpretation of MRI scans.3 To 
ensure that the diagnosis of MS is correct, clinical symptoms, neurological signs, and MRI 
findings must be correctly interpreted by an MS specialist neurologist and a neuroradiologist, 
who is an essential component of a specialist MS service. Making an accurate diagnosis of 
MS has become even more important with the advent of highly-effective treatments and the 
consequences of misdiagnosis can be severe; a number of MS therapies exacerbate 
neuromyelitis optica spectrum disorder6, while one of the first patients reported with 
natalizumab-associated progressive multifocal leukoencephalopathy (PML) did not have 
evidence MS at autopsy.7   
 
Once a diagnosis of RRMS is confirmed, it is necessary that the newly diagnosed patient 
receive emotional support and the information relevant to the management of their disease.8 
These two elements are important for patient satisfaction about the communication of the 
diagnosis of MS.8 A discussion of management should incorporate advice about lifestyle 
factors, including smoking cessation, since this will reduce their risk of comorbidities and 
long-term disease progression.9 This holistic approach to the communication of the MS 
diagnosis requires time and care, and can only be provided by a specialist MS clinic, 
involving an MS specialist nurse. If patients accept their disease better and take an active 
part in deciding the goals of treatment and formulating a management plan, it is more likely 
that they will be adherent and will have a better quality of life.  
 
A disease-modifying therapy is considered in patients with clinical and/or radiological 
evidence of active disease. There are now 13 FDA-approved treatments for RRMS, 
including five agents approved in the last five years alone. These agents have differing 
mechanisms of action, efficacy and safety profiles. Staying on top of the volume of data from 
clinical trials and post-marketing studies is challenge for even the most seasoned MS 
specialist and probably near impossible for a general neurologist. Comparisons between the 
results of the clinical trials, which may have an impact on the choice of the disease-
modifying drug, need to be done with caution and by an MS specialist neurologist. The 
multitude of treatment options makes counselling patients on the risks and benefits of 
treatment a complex and sometimes lengthy process. An MS specialist nurse, who may not 
be available to neurologists working in the general neurology setting, can support the 
process of treatment choice and initiation.  
 
A number of the recently approved treatments for RRMS are more efficacious than the 
established injectable agents, but are associated with potentially serious adverse effects, 
such as opportunistic infections and secondary autoimmunity. Because of the potential for 
severe, and even life-threatening complications, these treatments require much more 
intensive monitoring. For example, monthly blood tests and urinalysis in patients treated with 
alemtuzumab and 4 – 6 monthly surveillance MRI scans in natalizumab treated patients at 
high-risk of PML. For patients to be treated with these agents safely a well-organised 
monitoring system is required that will usually require a multi-disciplinary team including 
neurologists, MS nurses, pharmacists and neuroradiologists that is best delivered through a 
dedicated specialist clinic. 
 
Optimal management of RRMS extends beyond disease-modifying treatments. People with 
MS have chronic neurological symptoms that are often unpleasant and impact on physical, 
social and occupational functioning.10 Symptomatic treatments that target key symptoms, 
such as fatigue, bladder disturbance and ambulatory dysfunction, require co-ordinated multi-
disciplinary care from a range of health care professionals. A multi-disciplinary team can also 
evaluate the need for physiotherapy and rehabilitation. Attention to co-morbidities is also an 
essential part of MS care. Co-morbidities in people with MS is associated with an increased 
risk of death11 and hospitalizations12 and need to be actively managed. An MS specialist 
clinic is ideally placed to provide holistic MS care.  
 
There has been relatively little investigation of the benefits of sub-specialist care for people 
with RRMS. An area that has been studied is relapse clinics, where people with RRMS can 
self-refer for rapid assessment of new neurological symptoms. Relapse clinics have been 
shown to both decrease hospital admissions, but also reduce psychological distress in 
patients experiencing a relapse.13 There is much evidence from other disease areas that 
specialist care improves outcomes. Among neurological diseases, admission to a specialist 
stroke unit improves functional outcomes14 and reduces mortality in patients with acute 
stroke, while specialist multidisciplinary care improves survival in motor neurone disease.15 
In surgical specialties patient volume is an established predictor of perioperative 
complications and death in patients undergoing elective surgical procedures.16    
 
There are few areas of medicine that have seen such rapid advances in recent years as the 
changes that have occurred in the diagnosis and management of RRMS. Given the current, 
and likely increasing, complexity of managing RRMS access to well-resourced, specialist MS 
services is essential to effectively monitor and treat our patients and optimise long-term 
outcomes.   
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